Clinical trials: Restless Leg Syndrome
Restless Leg Syndrome (RLS)
Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment
The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS).
- Trial name
- RLS-DRD2gene (NCT06726785)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HBC Immunology Inc
Parkinson's Disease, Restless Leg Syndrome
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00673088
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Parkinson's Disease, Restless Leg Syndrome
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment…
- Trial name
- NCT00674310
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Idiopathic Restless Leg Syndrome
Rotigotine Restless Legs Syndrome Dose Finding Trial
The objective of this trial is to demonstrate clinical efficacy of four different dosages of SPM 962 1.125 mg, 2.25 mg, 4.5 mg and 6.75 mg (corresponding to 2.5 cm2, 5 cm2, 10 cm2 and 15 cm2 patch size respectively) in RLS…
- Trial name
- NCT00243217
- Testing
- SPM 936
- Where
- Germany
- Volunteers
- 341 people
- Sponsor
- UCB Pharma